Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Optinose Inc (OPTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 388,294
  • Shares Outstanding, K 41,264
  • Annual Sales, $ 7,070 K
  • Annual Income, $ -106,660 K
  • 60-Month Beta 0.65
  • Price/Sales 54.90
  • Price/Cash Flow N/A
  • Price/Book 3.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.71
  • Number of Estimates 2
  • High Estimate -0.68
  • Low Estimate -0.73
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +12.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.77 +41.06%
on 02/25/19
9.77 -2.25%
on 03/06/19
+2.28 (+31.36%)
since 02/21/19
3-Month
5.72 +66.96%
on 12/24/18
9.77 -2.25%
on 03/06/19
+3.54 (+58.90%)
since 12/21/18
52-Week
5.66 +68.73%
on 12/21/18
30.00 -68.17%
on 07/09/18
-10.21 (-51.67%)
since 03/21/18

Most Recent Stories

More News
Option Care ASPEN Study Shows Clinical Interventions in Home Nutrition Patients Reduce Readmissions, Save Costs

Clinical interventions provided by a nutrition support team can prevent hospital readmission in patients with short bowel syndrome (SBS) receiving home parenteral nutrition (PN), saving millions...

OPTN : 9.70 (+3.08%)
Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights

Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million

OPTN : 9.70 (+3.08%)
Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth...

OPTN : 9.70 (+3.08%)
Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will present clinical and health economic...

OPTN : 9.70 (+3.08%)
Optinose Announces License Agreement

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

OPTN : 9.70 (+3.08%)
Sosei Heptares Announces Medicxi to Invest Up To EUR 40 Million in New Collaboration Based on its Orexin Agonist Program

Sosei Group Corporation ("the Company") (TSE: 4565), announces it has entered into a structured financing agreement[1] with Medicxi, a venture fund dedicated to financing asset-centric companies, to form...

SOLTF : 11.2900 (-4.16%)
OPTN : 9.70 (+3.08%)
Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of eBay Inc. (NASDAQ:EBAY),...

DSGX : 35.79 (+1.13%)
EOLS : 24.50 (-2.43%)
EBAY : 37.32 (+1.69%)
PLSE : 19.34 (+2.38%)
WB : 60.35 (-1.08%)
OPTN : 9.70 (+3.08%)
Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received written notice from Avanir Pharmaceuticals,...

OPTN : 9.70 (+3.08%)
Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced today the enrollment of the first patient in a global clinical...

OPTN : 9.70 (+3.08%)
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present...

OPTN : 9.70 (+3.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade OPTN with:

Business Summary

OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and...

See More

Key Turning Points

2nd Resistance Point 9.98
1st Resistance Point 9.70
Last Price 9.70
1st Support Level 9.12
2nd Support Level 8.82

See More

52-Week High 30.00
Fibonacci 61.8% 20.70
Fibonacci 50% 17.83
Fibonacci 38.2% 14.96
Last Price 9.70
52-Week Low 5.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar